Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab
A high GNRI level during PEM therapy is an important prognostic indicator in patients with mUC. A sustained GNRI is a predictive biomarker for PFS and OS.
Authors
- Moeko Iida (ORCID: https://orcid.org/0009-0001-5814-6825)
- Nanami Ito (ORCID: https://orcid.org/0000-0002-0548-1654)
- Yuji Hotta
- Nobuhiko Shimizu (ORCID: https://orcid.org/0000-0001-7280-2481)
- Yoshihiko Tasaki (ORCID: https://orcid.org/0000-0002-1830-7452)
- Yosuke Sugiyama (ORCID: https://orcid.org/0000-0001-8436-5872)
- Yoshihisa Mimura
- Yuka Kimura (ORCID: https://orcid.org/0009-0001-6392-6770)
- Yoko Furukawa-Hibi
- T. Nagai
- T. Etani
- M. Tomita
- Daiki Ishikawa (ORCID: https://orcid.org/0009-0007-7975-2983)
- TAKAHIRO YASUI
- KUNIHIRO ODAGIRI
- TAKU NAIKI
- TOSHIHARU MORIKAWA
Institutions
- Nagoya City University (JP)
- Nagoya City University Hospital (JP)
- Nagoya Medical Center (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-03-27
- DOI
- https://doi.org/10.21873/anticanres.18107
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00